Samsara BioCapital GP, LLC - 05 Mar 2024 Form 4 Insider Report for vTv Therapeutics Inc. (VTVT)

Role
10%+ Owner
Signature
Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member
Issuer symbol
VTVT
Transactions as of
05 Mar 2024
Net transactions value
$0
Form type
4
Filing time
06 Dec 2024, 16:15:18 UTC
Previous filing
29 Feb 2024
Next filing
03 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTVT Class A Common Stock Other -58,836 -22% 206,784 05 Mar 2024 By Samsara BioCapital, L.P. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTVT Pre- Funded Warrants (Right to Buy) Award +58,885 +7.1% 892,578 05 Mar 2024 Class A Common Stock 58,885 $0.0100 Samsara BioCapital, L.P. F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Samsara BioCapital GP, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share.
F2 These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports.
F3 The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.